OncoBEAM™ NRAS

  • The OncoBEAM™ NRAS test is a bead-based digital PCR approach (also called BEAMing Digital PCR) allowing for the detection of up to 5 different mutations within the NRAS gene from a single sample.
  • Mutations covered:
    Q61K, Q61R, Q61L, Q61H

Documents

All
  • All
  • Brochure
Documents

Neuroblastoma RAS viral oncogene homolog (NRAS) is a member of the RAS family of protein kinases playing a key role within the MAPK signaling pathway. NRAS is involved in important cell functions including cell growth, differentiation and survival.

Recent data has shown that NRAS mutation status may be a predictive factor for anti-EGFR therapy response in colorectal cancer as well as for BRAF inhibitor response in metastatic melanoma patients. The mutation status of the NRAS gene is of particular relevance in clinical research and patient care (1,2).

 

* FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

BACK TO LIST

Mutations

Mutations

Clinical Relevance

Clinical Relevance

Cancer Relevance

  • Melanoma
  • Colorectal cancer

Drug Relevance

  • Anti-EGFR therapies including cetuximab (Erbitux®) and panitumumab (Vectibix®)
  • Novel small molecule inhibitors (RAF, MEK)
Test Details

Test Details

Turn around times

  • Batch analysis <4 weeks
  • Single samples < 10 days

Sample Requirements

  • Serum/Plasma
    ≥ 2 ml
  • Whole blood
    10 ml
  • FFPE/Frozen Tissue
    3 sections at 5 μm
References

References

  1. Nazarian R et al. (2010) Nature 468:973-977.
  2. Mao C et al. (2010) Lancet Oncology 11:753-762
Contact

Sales Support

info@sysmex-inostics.com

Create Pdf